Orthocell Unlocks 221 U.S. Military Hospitals for Nerve Repair Device
Orthocell unlocks access to 221 U.S. military and veteran hospitals for Remplir nerve repair device
Orthocell (ASX: OCC) has secured approval to supply its Remplir nerve repair device across the United States Department of Defence and Veterans Affairs hospital networks, gaining access to 51 DoD military hospitals and 170 VA medical centres. The approval, announced on 15 April 2026, more than doubles the company’s addressable U.S. hospital footprint and arrives as management reports “increasing commercialisation and revenue momentum” in the American market.
The military and veteran healthcare approval adds 221 facilities to Orthocell’s existing U.S. presence, which already includes 32 Value Analysis Committee (VAC) approvals covering over 115 civilian hospitals, with a further 57 VAC applications currently pending. The company’s established distributor network, which covers 17 U.S. states, will target military and VA surgeons operating within these hospital systems, with management noting that a significant portion of these facilities can be serviced by existing distribution infrastructure.
When big ASX news breaks, our subscribers know first
What is peripheral nerve repair and why does it matter for trauma surgery?
Peripheral nerve injuries involve damage to nerves outside the brain and spinal cord, commonly caused by traumatic accidents, blast injuries, surgical complications, or combat-related wounds. When nerves are severed or damaged, they require surgical reconstruction to restore sensation and motor function to affected limbs and body parts.
Remplir is a collagen-based medical device that provides a scaffold for nerve regeneration. During surgery, the device bridges gaps in damaged nerves, creating a pathway along which nerve fibres can regrow and reconnect. This type of reconstructive procedure is particularly relevant in military and veteran populations, where blast injuries, complex trauma, and limb-threatening wounds create acute demand for advanced nerve repair solutions.
Military healthcare systems represent a specialised but substantial market segment with concentrated surgical expertise in trauma reconstruction. Real-world battlefield validation provides clinical credibility that can influence surgeon adoption patterns across both military and civilian trauma centres.
Battlefield validation in Ukraine demonstrates Remplir’s real-world performance
Remplir has been deployed in 23 surgical procedures on injured soldiers in Ukraine, across both primary and secondary nerve repair applications. The battlefield experience validated key device attributes including portability, ease of use, and suitability for treating major traumatic injuries under logistically constrained conditions where time and resources are limited.
The Ukraine deployment demonstrates that Remplir performs in demanding conflict environments where traditional medical infrastructure may be compromised. Surgeons operating in field conditions require devices that can be transported easily, stored without complex refrigeration requirements, and deployed rapidly during critical procedures.
Paul Anderson, Managing Director
“Remplir has already demonstrated its value in conflict-related injuries in Ukraine, highlighting its suitability for the types of trauma commonly encountered within military healthcare systems.”
This conflict deployment provides differentiated clinical validation that competitors may lack. Real-world military use cases directly support the commercial rationale for DoD and VA adoption, as surgeons treating combat casualties seek proven solutions that have performed under battlefield conditions.
U.S. commercial momentum building across multiple fronts
The DoD and VA approval forms part of a broader U.S. commercialisation acceleration, not an isolated regulatory milestone. Orthocell’s multi-channel strategy combines a distributor network spanning 17 states, in-house sales teams, and medical education resources to drive surgeon adoption.
The company’s existing civilian hospital pipeline includes 32 VAC approvals secured, providing access to over 115 hospitals, with 57 applications currently pending resolution. Management has stated that existing distribution footprint can immediately service “a significant portion” of military and VA facilities, supporting efficient market penetration without requiring substantial new infrastructure investment.
| Market Segment | Facilities Accessible | Status |
|---|---|---|
| DoD Military Hospitals | 51 | Approved |
| VA Medical Centres | 170 | Approved |
| Civilian Hospitals (VAC approved) | 115+ | Active |
| Civilian Hospitals (VAC pending) | 57 applications | Pending |
The converging approvals across military, veteran, and civilian hospital systems create compounding commercial momentum. Distributor network leverage means lower incremental cost to capture new market segments, as the same regional sales infrastructure can service both military facilities and civilian trauma centres within overlapping geographies.
Remplir’s expanding global footprint supports the investment case
Remplir has secured regulatory clearance across multiple jurisdictions, de-risking the technology platform and creating optionality for revenue diversification. The device is approved in the United States (FDA cleared), Australia, New Zealand, Singapore, Thailand, Canada, and Hong Kong.
Device Technologies Group handles distribution across Australia, New Zealand, and Singapore, whilst Orthocell’s own U.S. distributor network manages American market penetration. The company’s broader product portfolio includes Striate+, a dental regeneration product distributed globally by BioHorizons Implant Systems, and SmrtGraft, a tendon repair technology currently in clinical development.
Key approved markets for Remplir include:
- United States (FDA cleared)
- Australia
- New Zealand
- Singapore
- Thailand
- Canada
- Hong Kong
Whilst the United States remains the primary commercial focus given market size and pricing dynamics, global regulatory approvals provide additional growth vectors and reduce dependence on a single geographic market. Multi-market clearances also validate the underlying collagen scaffold technology across different regulatory frameworks, supporting future product development pathways.
The next major ASX story will hit our subscribers first
What comes next for Orthocell’s U.S. expansion
Near-term priorities centre on leveraging the existing distributor network to engage military and VA surgeons, whilst pursuing resolution of the 57 pending civilian VAC applications. Management has stated its intent to “increase utilisation of Remplir across key U.S. healthcare segments”, indicating an active commercialisation push across both military and civilian trauma channels.
The company possesses established infrastructure to support this expansion, including distributor coverage across 17 states, in-house sales teams, and medical education resources that can be deployed to train surgeons on Remplir surgical techniques.
Key near-term catalysts include:
- Distributor-led engagement with DoD and VA surgeons across newly accessible military and veteran facilities
- Resolution of 57 pending civilian VAC applications, which could add substantial additional hospital access
- Continued geographic expansion of U.S. distributor network beyond the current 17-state footprint
The commercial pathway provides identifiable near-term catalysts for revenue growth. Operational leverage through existing distribution infrastructure supports margin expansion as procedure volumes scale, reducing the incremental cost of each additional surgeon trained and each new facility serviced. Orthocell’s ability to execute on this expanded market access will determine whether the regulatory milestone translates into material revenue acceleration across the military, veteran, and civilian trauma segments.
Don’t Miss the Next Biotech Breakthrough in U.S. Healthcare
Join 20,000+ investors receiving FREE breaking ASX news within minutes of release, complete with in-depth analysis. The Big News Blast delivers market-moving announcements from Healthcare, Technology, Finance and other non-resource sectors straight to your inbox. Click the “Free Alerts” button to get ahead of the next opportunity.